{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:35Z","timestamp":1777509215005,"version":"3.51.4"},"reference-count":57,"publisher":"American Psychiatric Association Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2004,3,1]]},"DOI":"10.1176\/appi.ajp.161.3.429","type":"journal-article","created":{"date-parts":[[2004,3,2]],"date-time":"2004-03-02T01:41:02Z","timestamp":1078191662000},"page":"429-435","source":"Crossref","is-referenced-by-count":39,"title":["Mania During Treatment of Chronic Hepatitis C  With Pegylated Interferon and Ribavirin"],"prefix":"10.1176","volume":"161","author":[{"given":"Chiadi U.","family":"Onyike","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine G.","family":"Lyketsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn J.","family":"Treisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"R1613BABBDJHI","doi-asserted-by":"crossref","unstructured":"Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35\u201347","DOI":"10.1046\/j.1365-2893.1999.6120139.x"},{"key":"R1613BABCJGJH","doi-asserted-by":"crossref","unstructured":"Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556\u2013562","DOI":"10.1056\/NEJM199908193410802"},{"key":"R1613BABIAAID","doi-asserted-by":"crossref","unstructured":"Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001; 345:41\u201352","DOI":"10.1056\/NEJM200107053450107"},{"key":"R1613BABBDJAJ","doi-asserted-by":"crossref","unstructured":"Leigh JP, Bowlus CL, Leistikow BN, Schenker M: Costs of hepatitis C. Arch Intern Med 2001; 161:2231\u20132237","DOI":"10.1001\/archinte.161.18.2231"},{"key":"R1613BABDBCAE","unstructured":"Management of Hepatitis C:2002: Consensus Statements: NIH Consensus Development Program, vol 19, number 1. Bethesda, Md, National Institutes of Health, 2002, pp 1\u201344"},{"key":"R1613BABBJGIG","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958\u2013965","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"R1613BABHCDJG","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975\u2013982","DOI":"10.1056\/NEJMoa020047"},{"key":"R1613BABHCICB","doi-asserted-by":"crossref","unstructured":"Trask PC, Esper P, Riba M, Redman B: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18:2316\u20132326","DOI":"10.1200\/JCO.2000.18.11.2316"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Lerner DM, Stoudemire A, Rosenstein DL: Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999; 40:428\u2013435","DOI":"10.1016\/S0033-3182(99)71208-9"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M: Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci 1997; 51:175\u2013180","DOI":"10.1111\/j.1440-1819.1997.tb02579.x"},{"key":"R1613BABFDJDI","doi-asserted-by":"crossref","unstructured":"Yokoyama A, Kimura Y, Shigemura J: Psychiatric side effects of interferon. J Toxicol Sci 1996; 21:93\u201396","DOI":"10.2131\/jts.21.93"},{"key":"R1613BABBHGGD","doi-asserted-by":"crossref","unstructured":"Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T, Maruyama K, Sakata I: Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998; 24:581\u2013583","DOI":"10.1016\/S0305-4179(98)00073-4"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C, Clemens J: Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2001; 42:365\u2013367","DOI":"10.1176\/appi.psy.42.4.365"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Janssen HL, Brouwer JT, van der Mast RC, Schalm SW: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241\u2013243","DOI":"10.1016\/S0168-8278(05)80402-7"},{"key":"R1613BABJEFDF","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38\u201347","DOI":"10.1016\/S0168-8278(96)80184-X"},{"key":"R1613BABGFJFJ","unstructured":"Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P: Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7:165\u2013168"},{"key":"R1613BABFCICA","doi-asserted-by":"crossref","unstructured":"el-Serag HB, Kunik M, Richardson P, Rabeneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123:476\u2013482","DOI":"10.1053\/gast.2002.34750"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, Ewing SL, Ho SB: Spectrum of disease in US veteran patients with hepatitis C. Am J Gastroenterol 2002; 97:1813\u20131820","DOI":"10.1111\/j.1572-0241.2002.05800.x"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ: Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001; 42:411\u2013415","DOI":"10.1176\/appi.psy.42.5.411"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31\u201337","DOI":"10.2105\/AJPH.91.1.31"},{"key":"R1613BABBCBFG","doi-asserted-by":"crossref","unstructured":"Dinwiddie SH, Shicker L, Newman T: Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160:172\u2013174","DOI":"10.1176\/appi.ajp.160.1.172"},{"key":"R1613BABCEHIF","doi-asserted-by":"crossref","unstructured":"Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE: Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655\u2013661","DOI":"10.2105\/AJPH.86.5.655"},{"key":"R1613BABBEJGJ","doi-asserted-by":"crossref","unstructured":"Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE: Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212\u2013220","DOI":"10.1097\/00005792-199507000-00005"},{"key":"R1613BABCBHDE","unstructured":"Van Thiel DH, Friedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A: Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998; 45:328\u2013330"},{"key":"R1613BABGGABI","doi-asserted-by":"crossref","unstructured":"Rosen HR: Hepatitis C in the liver transplant recipient: current understanding and treatment. Microbes Infect 2002; 4:1253\u20131258","DOI":"10.1016\/S1286-4579(02)01653-2"},{"key":"R1613BABHBGGC","unstructured":"Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M: Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001; 46:2060\u20132065"},{"key":"R1613BABIJBGD","doi-asserted-by":"crossref","unstructured":"Altindag A, Ozbulut O, Ozen S, Ucmak H: Interferon-alpha-induced mood disorder with manic features. Gen Hosp Psychiatry 2001; 23:168\u2013170","DOI":"10.1016\/S0163-8343(01)00135-9"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Bozikas V, Petrikis P, Balla A, Karavatos A: An interferon-alpha-induced psychotic disorder in a patient with chronic hepatitis C. Eur Psychiatry 2001; 16:136\u2013137","DOI":"10.1016\/S0924-9338(01)00554-5"},{"key":"R1613BABEIDEG","doi-asserted-by":"crossref","unstructured":"Garcia-Pares G, Domenech C, Gil M: Psychosis induced by interferon-alpha. Psychosomatics 2002; 43:428\u2013429","DOI":"10.1176\/appi.psy.43.5.428"},{"key":"R1613BABIEGAE","doi-asserted-by":"crossref","unstructured":"Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG: Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89:356\u2013362","DOI":"10.1002\/1097-0142(20000715)89:2<356::AID-CNCR21>3.3.CO;2-Q"},{"key":"atypb9","doi-asserted-by":"crossref","unstructured":"Iancu I, Sverdlik A, Dannon PN, Lepkifker E: Bipolar disorder associated with interferon-alpha treatment. Postgrad Med J 1997; 73:834\u2013835","DOI":"10.1136\/pgmj.73.866.834"},{"key":"R1613BABHBHED","doi-asserted-by":"crossref","unstructured":"Kanno A, Yamada M, Abe M, Okamoto Y: A case of interferon alpha-induced manic psychosis in chronic hepatitis C. Tohoku J Exp Med 1999; 187:79\u201382","DOI":"10.1620\/tjem.187.79"},{"key":"R1613BABDAIDG","doi-asserted-by":"crossref","unstructured":"Monji A, Yoshida I, Tashiro K, Hayashi Y, Tashiro N: A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics 1998; 39:562\u2013564","DOI":"10.1016\/S0033-3182(98)71296-4"},{"key":"R1613BABIFFBC","doi-asserted-by":"crossref","unstructured":"Schafer M, Boetsch T, Laakmann G: Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000; 95:1101\u20131104","DOI":"10.1046\/j.1360-0443.2000.957110111.x"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"Strite D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9:273\u2013276","DOI":"10.1176\/jnp.9.2.273"},{"key":"R1613BABFFDDB","doi-asserted-by":"crossref","unstructured":"Howes OD, McKenzie KJ: Manic psychosis induced by long term alpha-interferon treatment for hepatitis. Int J Psychiatry Clin Pract 2000; 4:161\u2013162","DOI":"10.3109\/13651500009178004"},{"key":"R1613BABFHHDB","doi-asserted-by":"crossref","unstructured":"Thome J, Knopf U: Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry 2003; 18:142\u2013143","DOI":"10.1016\/S0924-9338(03)00032-4"},{"key":"R1613BABFFJJJ","doi-asserted-by":"crossref","unstructured":"Kingsley D: Interferon-alpha induced \u201ctertiary mania.\u201d Hosp Med 1999; 60:381\u2013382","DOI":"10.12968\/hosp.1999.60.5.1123"},{"key":"R1613BABJHBEE","doi-asserted-by":"crossref","unstructured":"Carpiniello B, Orru MG, Baita A, Pariante CM, Farci G: Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998; 55:88\u201389","DOI":"10.1001\/archpsyc.55.1.88"},{"key":"R1613BABFJFAF","doi-asserted-by":"crossref","unstructured":"Rossi A, Renzetti D, D\u2019Albenzio L, Gianfelice D, Kalyvoka A, Rinaldi O: Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder. Psychiatry Clin Neurosci 2002; 56:647\u2013648","DOI":"10.1046\/j.1440-1819.2002.01070.x"},{"key":"R1613BABBJCGB","doi-asserted-by":"crossref","unstructured":"Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577\u20131580","DOI":"10.1001\/archinte.147.9.1577"},{"key":"R1613BABHAIDI","doi-asserted-by":"crossref","unstructured":"Adams F, Fernandez F, Mavligit G: Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6:355\u2013359","DOI":"10.1007\/BF00177432"},{"key":"R1613BABHECJG","doi-asserted-by":"crossref","unstructured":"Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54:565\u2013572","DOI":"10.1046\/j.1440-1819.2000.00754.x"},{"key":"R1613BABGDEFJ","doi-asserted-by":"crossref","unstructured":"Felker BL, Sloan KL, Dominitz JA, Barnes RF: The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry 2003; 160:174\u2013178","DOI":"10.1176\/appi.ajp.160.1.174"},{"key":"R1613BABGACGA","doi-asserted-by":"crossref","unstructured":"Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B: Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131\u2013132","DOI":"10.1016\/S0140-6736(98)04793-X"},{"key":"R1613BABIJDJF","doi-asserted-by":"crossref","unstructured":"Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C: Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15:300\u2013303","DOI":"10.1046\/j.1440-1746.2000.02090.x"},{"key":"R1613BABIJHHC","doi-asserted-by":"crossref","unstructured":"Gleason OC, Yates WR: Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40:510\u2013512","DOI":"10.1016\/S0033-3182(99)71190-4"},{"key":"atypb12","unstructured":"Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88:760\u2013761"},{"key":"atypb13","doi-asserted-by":"crossref","unstructured":"Schramm TM, Lawford BR, Macdonald GA, Cooksley WG: Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173:359\u2013361","DOI":"10.5694\/j.1326-5377.2000.tb125687.x"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Goldman LS: Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35:412\u2013413","DOI":"10.1016\/S0033-3182(94)71769-2"},{"key":"atypb15","doi-asserted-by":"crossref","unstructured":"Valentine AD, Meyers CA: Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics 1995; 36:418\u2013419","DOI":"10.1016\/S0033-3182(95)71658-9"},{"key":"R1613BABCCDBJ","doi-asserted-by":"crossref","unstructured":"Farah A: Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002; 63:166\u2013167","DOI":"10.4088\/JCP.v63n0213c"},{"key":"R1613BABHEJCF","doi-asserted-by":"crossref","unstructured":"Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M: Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16:1091\u20131099","DOI":"10.1046\/j.1365-2036.2002.01265.x"},{"key":"R1613BABICDJG","doi-asserted-by":"crossref","unstructured":"Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942\u2013947","DOI":"10.1038\/sj.mp.4001119"},{"key":"R1613BABCIAHJ","doi-asserted-by":"crossref","unstructured":"Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J, Kling MA, Valentine AD, Meyers CA: Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41:439\u2013441","DOI":"10.1176\/appi.psy.41.5.439"},{"key":"R1613BABCJEJA","doi-asserted-by":"crossref","unstructured":"Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344:961\u2013966","DOI":"10.1056\/NEJM200103293441303"},{"key":"R1613BABGEACA","doi-asserted-by":"crossref","unstructured":"Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M: Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000; 33:72\u201374","DOI":"10.1055\/s-2000-8450"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.161.3.429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T09:58:02Z","timestamp":1722419882000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.161.3.429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3,1]]}},"alternative-id":["10.1176\/appi.ajp.161.3.429"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.161.3.429","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}